OptiCel is formulated with selected nutraceuticals including polyphenols (e.g. curcumin, quercetin, resveratrol, epigallocatechin gallate and proanthocyanidins), minerals (e. g. Mg), and vitamins (e.g. vitamins K, vitamin D) to help maintain overall wellness thereby reduce risks of chronic metabolic diseases, including heart disease, diabetes, high blood pressure, kidney disease, osteoporosis, arthritis, etc. development and progression.  The unique bioactives in OptiCel work at the cellular level: 

• Data generated from in vitro and animal studies have shown the bioactives of OptiCel formula prevent/reduce the risks for major chronic diseases such as heart disease, osteoporosis, diabetes, obesity, hypertension and arthritis by modulating growth factors (e.g. bone morphogenic proteins, and transforming growth factors), transcription factors (e.g. Runx2, PPAR-y, C/EBP α, SREBP-1, hypoxia induced factor-1α, Sox9, nuclear factor-κB), signalling pathways (e.g. SIRT1, AMPK, Wnt/β-catenin, MAPKs), and proinflammatory cytokines (TNF-α, IL-6 and IL-1) at cellular level (34-43).

• These mediators of OptiCel bioactives work at the cellular level by either inhibiting the triggers or inducing the suppressors of chronic diseases’ development and progression in the various tissues and organs of the body (21-29, 33). 

 

Clinical Studies 

Multiple clinical studies have shown repeated consumption of the bio-actives in OptiCel, including curcumin, quercetin, resveratrol, magnesium (Mg), epigallocatechin gallate (EGCG), proanthocyanidins, and vitamin K2, to have significant effect in preventing/reducing the prevalence and/or risks of heart disease, diabetes, hypertension, arthritis and osteoporosis (1-16 ).   

• Clinical studies with quercetin (1, 12), resveratrol (4, 7), curcumin as Theracurmin® (10), magnesium (17, 18) or green tea extract (GTE) with EGCG as the major component (19), significantly reduced blood pressure.
• Multiple clinical studies with curcumin (2), magnesium (6,11, 20), resveratrol (4, 7, 13) and GTE (rich in EGCG) (21, 22) have shown significant reduction in diabetes as indicated by (a) an increase in insulin sensitivity, and (b) reduction in insulin resistance, glucose level, and HbA1c. 
• In separate clinical studies, magnesium (23) and vitamin K2 as Menaquinone-7 (MenaQ7®) (16) prevented bone loss as indicated by a significant increase in lumber spine, femoral neck, hip bone mineral content and bone mass density.
• Clinical studies with magnesium, curcumin, resveratrol and EGCG improved heart health by increasing HDL cholesterol and decreasing triglycerides and total cholesterol (4, 6, 24, 14, 25). 
• In clinical studies, Vitamin K2 as MenaQ7® (8) and magnesium (26) supplementation promoted heart health as demonstrated by significant reduction in arterial stiffness.
• Clinical studies with Curcumin as Theracurmin® (9), quercetin (5) and oligomeric anthocyanidins as Pycnogenol (3, 15, 27-29) significantly reduced arthritis (osteoarthritis and rheumatoid arthritis) as demonstrated by significant reduction in pain, morning stiffness and physical performance.
• Clinical studies with curcumin as Theracurmin®, and quercetin as EMIQ® indicated these bioactives to be 27 times, and 17 times more bioavailable, respectively, when compared to their respective standard powders (curcumin and quercetin) (30, 31).  In addition, vitamin K2 as MenaQ7® has been shown to be 7-8 times more bioavailable than K1, which is commonly found in foods and used in food fortification (32). Also, magnesium from dimagnesium malate®  is 1.8 times more bioavailable than that from magnesium oxide (33).

References:

1. Edwards RL, et al. (2007). Quercetin Reduces Blood Pressure in Hypertensive Subjects. J. Nutr. 137: 2405-2411.
2. Chuengsamarn s, et al. (2012). Curcumin Extract for Prevention of Type 2 Diabetes. Diabetes Care 35:2121–2127, 2012.
3. M O N O G R A P H SCIENTIFIC AND CLINICAL FOR PROPRIETARY BOTANICAL INGREDIENT for PYCNOGENOL®. abc.herbalgram.org › DocServer › Pycnog_FullMono012019-final-FULL.  
4. Movahed A, et al. ( 2013). Antihyperglycemic Effects of short term Resveratrol Supplementation in Type 2 Diabetic Patients. Evidence-Based Complementary and Alternative Medicine. http://dx.doi.org/10.1155/2013/851267.
5. Javadi S, et al. 2016. The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial. http://dx.doi.org/10.1080/07315724.2016.1140093.
6. Guerrero-Romero F, et al. (2014). Oral magnesium supplementation improves glycemic status in subjects with prediabetes and hypomagnesaemia: A double-blind placebo-controlled randomized trial. Diabetes Metab; 30: 253-258. DOI: http://dx.doi.org/10.1016/j.diabet.2015.03.010
7. Timmers S, et al. (2011). Calorie restriction-like effects of 30 days of Resveratrol (resVida™) supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011 November 2; 14(5). doi:10.1016/j.cmet.2011.10.002.
8. Knapen MHJ; et al. 2015. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: double-blind randomized clinical trial. http://dx.doi.org/10.1160/TH14-08-0675 Thromb Haemost 2015; 113.
9. Nakagawa Y, et al. 2014. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci. DOI 10.1007/s00776-014-0633-0.
10. Akazawa N, et al. (2012). Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women. Nutrition Research, 32795–799.
11. Rodriguez-Moran et al. (2003). Oral Magnesium Supplementation Improves Insulin Sensitivity and Metabolic Control in Type 2 Diabetic Subjects: A randomized double-blind controlled trial. Diabetes Care 26:1147–1152, 2003.
12. Egert S, et al. 2009). Quercetin reduces systolic blood pressure and plasma oxidized low-density lipoprotein concentrations in overweight subjects. British Journal of Nutrition (2009), 102, 1065–1074 doi:10.1017/S0007114509359
13. Brasnyo P, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. British Journal of Nutrition (2011), 106, 383–38.
14. Liu CY, et al. (2014). Effects of Green Tea Extract on Insulin Resistance and Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes and Lipid Abnormalities: A Randomized, Double-Blinded, and Placebo-Controlled Trial. PLoS ONE 9(3): e91163. doi:10.1371/journal.pone.0091163.
15. Rohdewald PG. Review on Sustained Relief of Osteoarthritis Symptoms with a Proprietary Extract from Pine Bark, Pycnogenol. JOURNAL OF MEDICINAL FOOD. J Med Food 21 (1) 2018, 1–4
16. Knapen MH, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013 Sep;24(9):2499-507. doi: 10.1007/s00198-013-2325-6. Epub 2013 Mar 23.
17. Kass L, et al. (2012). Eff ect of magnesium supplementation on blood pressure: a meta-analysis. European Journal of Clinical Nutrition (2012) 66, 411—418.
18. Kass LS, et al. (2013). A Pilot Study on the Effects of Magnesium Supplementation with High and Low Habitual Dietary Magnesium Intake on Resting and Recovery from Aerobic and Resistance Exercise and Systolic Blood Pressure. Journal of Sports Science and Medicine (2013) 12, 144-150.
19. Peng X, et al. (2014). Effect of green tea consumption on blood pressure: A meta-analysis of 13 randomized controlled trials. SCIENTIFIC REPORTS | 4 :6251 |DOI:10.1038/srep06251.
20. Topraka O, et al. Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study. Kidney Blood Press Res 2017; 42:33-42.
21. Liu CH, et al. (2014). Effects of Green Tea Extract on Insulin Resistance and Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes and Lipid Abnormalities: A Randomized, Double-Blinded, and Placebo-Controlled Trial. PLoS ONE 9(3): e91163. doi:10.1371/journal.pone.0091163.
22. Liu, K. et al. Effect of green tea on glucose control and insulin sensitivity: A meta-analysis of 17 randomized controlled trials. Am J Clin Nutr. 98, 340–348 (2013).
23. Carpenter TO, et al. (). A Randomized Controlled Study of Effects of Dietary Magnesium Oxide Supplementation on Bone Mineral Content in Healthy Girls. J Clin Endocrinol Metab. 2006; 91(12): 4866–4872. doi:10.1210/jc.2006-1391.
24. Qin S, et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutrition Journal (2017) 16:68. DOI 10.1186/s12937-017-0293-y.
25. Soni KB1, Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. 1992 Oct;36(4):273-5.
26. Joris PJ, et al. Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial1–3. Am J Clin Nutr 2016;103:1260–6.
27. Faird R, Mireizi Z, Mirheidari M, et al. Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis. Nutr Res. 2007; 27: 692-697. doi: 10.1016/j. nutres. 2007.09.007.
28. Cisár P, Jány R, Waczulíková I, et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytother Res. 2008; 22(8): 1087-1092. doi: 10.1002/ptr.2461. 
29. Belcaro G, Cesarone MR, Errichi S, et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance, and vascular aspects. Phytother Res. 2008a;22(4):518-523. doi: 10.1002/ptr.2376.
30. Sasaki H, Sunagawa Y, Takahashi K, et al (2011): Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34: 660-5.
31. Makino T, et al. (2009) Enzymatically Modified Isoquercitrin, α-Oligoglucosyl Quercetin 3-OGlucoside, Is Absorbed More Easily than Other Quercetin Glycosides or Aglycone after Oral Administration in Rats. Biol. Pharm. Bull. 32(12) 2034—2040. 
32. Schurgers LJ, et al. Vitamin K–containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109:3279-3283.
33. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Evaluation of di-magnesium malate, used as a novel food ingredient and as a source of magnesium in foods for the general population, food supplements, total diet replacement for weight control and food for special medical purposes. EFSA Journal 2018;16(6):5292. doi: 10.2903/j.efsa.2018.5292.
34. Montes de Oca A, et al. (2014). Magnesium Inhibits Wnt/β-catenin Activity and Reverses the Osteogenic Transformation of Vascular Smooth Muscle Cells. PLOS ONE 9 (2): e89525.
35. Beazley KE, et al. (2013). Quercetin Attenuates Warfarin-induced Vascular Calcification in Vitro Independently from Matrix Gla Protein. J. Biol. Chem. 288: 2632-2640.
36. Wang S, et al. (2014). Novel insights of dietary polyphenols and obesity. J Nutr Biochem. , 25(1): 1–18. doi:10.1016/j.jnutbio.2013.09.001.
37. Aguirre L, et al (2011). Beneficial Effects of Quercetin on Obesity and Diabetes. The Open Nutraceuticals Journal, 2011, 4, 189-198 1891876-3960/11 2011 Bentham Open
38. Zhang D, et al. (2013). Curcumin and Diabetes: A Systematic Review. Evidence Based Complementary and Alternative Medicine; http://dx.doi.org/10.1155/2013/636053.
39. Babu PVA, et al. (2013) Recent Advances in Understanding the Anti-Diabetic Actions of Dietary Flavonoids. J Nutr Biochem. Doi: 10.1016/jnutbio.2013.06.003.
40. Dudaric L, et al. (2015). The role of polyphenols on bone health. Food Research International. http://dx.doi.org/10.1016/j.foodres.2015.10.017. http://www2.sunysuffolk.edu/pickenc/Bone.pdf
41. Salvamani S, et al. (2014). ,Antiartherosclerotic Effects of Plant Flavonoids. BioMed Research International http://dx.doi.org/10.1155/2014/480258.
42. Vinayagam R and Xu B (2015). Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutrition & Metabolism 12:60 DOI 10.1186/s12986-015-0057-7.
43. Sharan K, et al. (2009). Role of phytochemicals in the prevention of Menopausal bone loss: Evidence from in vitro, in vivo, human interventional and pharmacokinetic studies. Current Med. Chem. 16: 1138-1157.